ClotCare: Non-steroidal Anti-inflamatory Drugs (NSAIDs) Receive Greater Scrutiny in Wake of Vioxx Withdrawal

ClotCare: Blood Clots, Stroke, Heart Attack

Sunday, April 18, 2021

Home | DVT/PE | Blood Clots | Coumadin/Warfarin | New Patients | Self Testing | Email List | Donate

Pick a Topic: Home New Postings Patient Postings Clinician Postings Join Our Email List Useful Web Links CE Opportunities Training Programs Guidelines DVT & PE Stories Editorial Board Financial Support About ClotCare DVT Coalition Contact Us Find info on a: Specific Medicine or Treatment Type of Medicine or Treatment Condition or Medical Procedure Lab Test Procedure Management Issue ClotCare complies with the HONcode standard for trustworthy health information: verify here. ClotCare is a member organization of the Coalition to Prevent Deep Vein Thrombosis. Click here to learn more about the Coalition to Prevent Deep Vein Thrombosis and DVT Awareness Month, which is held each March.	Non-steroidal Anti-inflamatory Drugs (NSAIDs) Receive Greater Scrutiny in the Wake of Vioxx Withdrawal Marie B. Walker January 2005 As has been widely publicized in the major media outlets, the pharmaceutical company Merck pulled its non-steroidal anti-inflamatory drug (NSAID) Vioxx from the market in late September in response to a study indicating that the drug increases the risk of stroke and heart attack. Since the withdrawal of Vioxx, other drugs in this class have received greater scrutiny. Studies have suggested that drugs such as Celebrex, Bextra, and Aleve increase a patient's risk of stroke and heart attack. Below are links to news stories seen in the major media outlets relating to Celebrex, Bextra, and Aleve. FDA Asks Pfizer to Stop Misleading Celebrex Ads Read the story on Fox News Read the story on CNN Read the story on Reuters Celebrex and Naproxen (Aleve) May Increase Stroke & Heart Attack Risk Read the story on Fox News Read the story on CNN Read the story on Reuters	Have questions? Ask ClotCare. Send questions by email to webmaster@clotcare.org. ClotCare is a 501(c)(3) non-profit organization generously supported by your tax-deductible donations and grants from our industry supporters. New Postings: Click here to view full list of new postings
ClotCare Home \| New Postings \| Patient Postings \| Clinician Postings \| Join Our Email List \| Useful Web Links CE Opportunities \| Training Programs \| DVT & PE Stories \| Editorial Board \| Financial Support About ClotCare \| DVT Coalition \| Donate to ClotCare \| Contact Us
Key topics discussed on ClotCare include: Blood Clots \| Deep Vein Thrombosis (DVT) \| Pulmonary Embolism (PE) \| Atrial Fibrillation (A. Fib or AF) \| Heart Attack \| Stroke \| Transient Ischemic Attack (TIA) \| Mini Stroke \| Bleeding Complications \| Vascular Surgery \| Surgical Blood Clot Removal \| Warfarin \| Coumadin \| Lovenox \| Low Molecular Weight Heparin (LMWH) \| Heparin \| Anticoagulants \| Plavix \| Aspirin \| Antiplatelets \| Blood Thinners
Copyright 2000-2018 by ClotCare. All rights reserved. Terms, Conditions, & Privacy \| Image Copyright Information 19260 Stone Oak Parkway, Suite 101 \| San Antonio, TX 78258 \| 210-860-0487 Send comments to webmaster@clotcare.org. Sunday, April 18, 2021